Alphamab (Jiangsu) Biopharmaceuticals Co. Ltd. has identified new antibody-drug conjugate (ADC) comprising bispecific antibodies targeting HER2 covalently bound to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.